Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2017

Open Access 01-12-2017 | Review

Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis

Authors: Marta F. Bustamante, Ricard Garcia-Carbonell, Katrijn D. Whisenant, Monica Guma

Published in: Arthritis Research & Therapy | Issue 1/2017

Login to get access

Abstract

An increasing number of studies show how changes in intracellular metabolic pathways alter tumor and immune cell function. However, little information about metabolic changes in other cell types, including synovial fibroblasts, is available. In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) are the most common cell type at the pannus–cartilage junction and contribute to joint destruction through their production of cytokines, chemokines, and matrix-degrading molecules and by migrating and invading joint cartilage. In this review, we show that these cells differ from healthy synovial fibroblasts, not only in their marker expression, proto-oncogene expression, or their epigenetic changes, but also in their intracellular metabolism. These metabolic changes must occur due to the stressful microenvironment of inflamed tissues, where concentrations of crucial nutrients such as glucose, glutamine, and oxygen are spatially and temporally heterogeneous. In addition, these metabolic changes will increase metabolite exchange between fibroblast and other synovial cells, which can potentially be activated. Glucose and phospholipid metabolism as well as bioactive lipids, including sphingosine-1-phosphate and lysophosphatidic acid, among others, are involved in FLS activation. These metabolic changes likely contribute to FLS involvement in aspects of immune response initiation or abnormal immune responses and strongly contribute to joint destruction.
Literature
1.
Wilkinson LS, Pitsillides AA, Worrall JG, Edwards JC. Light microscopic characterization of the fibroblast-like synovial intimal cell (synoviocyte). Arthritis Rheum. 1992;35:1179–84.PubMedCrossRef
2.
Smith MD, Barg E, Weedon H, Papengelis V, Smeets T, Tak PP, et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. Ann Rheum Dis. 2003;62:303–7.PubMedPubMedCentralCrossRef
3.
4.
Krey PR, Scheinberg MA, Cohen AS. Fine structural analysis of rabbit synovial cells. II. Fine structure and rosette-forming cells of explant and monolayer cultures. Arthritis Rheum. 1976;19:581–92.PubMedCrossRef
5.
Okada Y, Nakanishi I, Kajikawa K. Ultrastructure of the mouse synovial membrane. Development and organization of the extracellular matrix. Arthritis Rheum. 1981;24:835–43.PubMedCrossRef
6.
Agarwal SK, Brenner MB. Role of adhesion molecules in synovial inflammation. Curr Opin Rheumatol. 2006;18:268–76.PubMedCrossRef
7.
Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007;315:1006–10.PubMedCrossRef
8.
Kiener HP, Watts GF, Cui Y, Wright J, Thornhill TS, Skold M, et al. Synovial fibroblasts self-direct multicellular lining architecture and synthetic function in three-dimensional organ culture. Arthritis Rheum. 2010;62:742–52.PubMedCrossRef
9.
Szekanecz Z, Koch AE. Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. Nat Rev Rheumatol. 2016;12:5–13.PubMedCrossRef
10.
Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al. Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis. 2008;67:402–8.PubMedCrossRef
11.
Fassbender HG. Specific and nonspecific structures developing in inflammatory rheumatic diseases. Acta Pathol Jpn. 1970;20:409–22.PubMed
12.
Ospelt C, Gay S. The role of resident synovial cells in destructive arthritis. Best Pract Res Clin Rheumatol. 2008;22:239–52.PubMedCrossRef
13.
Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 1997;61:1861–78.PubMedCrossRef
14.
Caulfield JP, Hein A, Dynesius-Trentham R, Trentham DE. Morphologic demonstration of two stages in the development of type II collagen-induced arthritis. Lab Invest. 1982;46:321–43.PubMed
15.
Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum. 2002;46:507–13.PubMedCrossRef
16.
Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity. 1998;28:197–208.PubMedCrossRef
17.
Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996;149:1607–15.PubMedPubMedCentral
18.
Lefevre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009;15:1414–20.PubMedPubMedCentralCrossRef
19.
Kraan MC, Haringman JJ, Weedon H, Barg EC, Smith MD, Ahern MJ, et al. T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2004;63:483–8.PubMedPubMedCentralCrossRef
20.
Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis. 2007;66:358–63.PubMedCrossRef
21.
22.
Ng CT, Biniecka M, Kennedy A, McCormick J, Fitzgerald O, Bresnihan B, et al. Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis. 2010;69:1389–95.PubMedPubMedCentralCrossRef
23.
Hammaker D, Sweeney S, Firestein GS. Signal transduction networks in rheumatoid arthritis. Ann Rheum Dis. 2003;62 Suppl 2:ii86–9.PubMedPubMedCentral
24.
Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis. 2006;65 Suppl 3:iii83–8.PubMedPubMedCentral
25.
Sweeney SE, Firestein GS. Primer: signal transduction in rheumatic disease--a clinician’s guide. Nat Clin Pract Rheumatol. 2007;3:651–60.PubMedCrossRef
26.
27.
28.
Yu XH, Zheng XL, Tang CK. Nuclear Factor-kappaB Activation as a Pathological Mechanism of Lipid Metabolism and Atherosclerosis. Adv Clin Chem. 2015;70:1–30.PubMedCrossRef
29.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85–95.PubMedCrossRef
30.
31.
Sanli T, Steinberg GR, Singh G, Tsakiridis T. AMP-activated protein kinase (AMPK) beyond metabolism: a novel genomic stress sensor participating in the DNA damage response pathway. Cancer Biol Ther. 2014;15:156–69.PubMedCrossRef
32.
Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, et al. PI3 kinase delta is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol. 2012;180:1906–16.PubMedCrossRef
33.
Fearon U, Canavan M, Biniecka M, Veale DJ. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat Rev Rheumatol. 2016;12:385–97.PubMedCrossRef
34.
Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis. 2005;64:971–80.PubMedPubMedCentralCrossRef
35.
Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol. 2016;12:169–82.PubMedCrossRef
36.
Wang T, Liu G, Wang R. The intercellular metabolic interplay between tumor and immune cells. Front Immunol. 2014;5:358.PubMedPubMedCentral
37.
38.
Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012;26:711–23.PubMedPubMedCentralCrossRef
39.
40.
Palmer CS, Ostrowski M, Balderson B, Christian N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol. 2015;6:1.PubMedPubMedCentralCrossRef
41.
Everts B, Pearce EJ. Metabolic control of dendritic cell activation and function: recent advances and clinical implications. Front Immunol. 2014;5:203.PubMedPubMedCentral
42.
43.
44.
Ramsay EE, Hogg PJ, Dilda PJ. Mitochondrial metabolism inhibitors for cancer therapy. Pharm Res. 2011;28:2731–44.PubMedCrossRef
45.
Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in health and disease. Nature. 2014;511:167–76.PubMedCrossRef
46.
McDonald G, Deepak S, Miguel L, Hall CJ, Isenberg DA, Magee AI, et al. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest. 2014;124:712–24.PubMedPubMedCentralCrossRef
47.
48.
Matsui T, Nakata N, Nagai S, Nakatani A, Takahashi M, Momose T, et al. Inflammatory cytokines and hypoxia contribute to 18 F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med. 2009;50:920–6.PubMedCrossRef
49.
Volchenkov R, Dung Cao M, Elgstoen KB, Goll GL, Eikvar K, Bjorneboe O, et al. Metabolic profiling of synovial tissue shows altered glucose and choline metabolism in rheumatoid arthritis samples. Scand J Rheumatol. 2016;46:160-1.
50.
Li M, Peng Z, Liu Q, Sun J, Yao S. Value of 11C-choline PET/CT for lung cancer diagnosis and the relation between choline metabolism and proliferation of cancer cells. Oncol Rep. 2013;29:205–11.PubMed
51.
Ahn JK, Kim S, Hwang J, Kim J, Kim KH, Cha HS. GC/TOF-MS-based metabolomic profiling in cultured fibroblast-like synoviocytes from rheumatoid arthritis. Joint Bone Spine. 2016.
52.
Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65:2015–23.PubMedPubMedCentralCrossRef
53.
Garcia-Carbonell R, Divakaruni AS, Lodi A, Vicente-Suarez I, Saha A, Cheroutre H, et al. Critical role of fibroblast-like synoviocytes glycolytic metabolism in rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1614-26.
54.
Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, et al. Dysregulated bioenergetics: a key regulator of joint inflammation. Ann Rheum Dis. 2016;75(12):2192-200. doi:10.​1136/​annrheumdis-2015-208476. Epub 2016 Mar 24.
55.
Zhao Y, Yan X, Li X, Zheng Y, Li S, Chang X. PGK1, a glucose metabolism enzyme, may play an important role in rheumatoid arthritis. Inflamm Res. 2016;65:815–25.PubMedCrossRef
56.
Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J Exp Med. 2013;210:2119–34.PubMedPubMedCentralCrossRef
57.
Yang Z, Shen Y, Oishi H, Matteson EL, Tian L, Goronzy JJ, et al. Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. Sci Transl Med. 2016;8:331ra38.PubMedPubMedCentralCrossRef
58.
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.PubMedPubMedCentralCrossRef
59.
Littlewood-Evans A, Sarret S, Apfel V, Loesle P, Dawson J, Zhang J, et al. GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. J Exp Med. 2016;213:1655–62.PubMedPubMedCentralCrossRef
60.
Sapieha P, Sirinyan M, Hamel D, Zaniolo K, Joyal JS, Cho JH, et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med. 2008;14:1067–76.PubMedCrossRef
61.
Mills E, O’Neill LA. Succinate: a metabolic signal in inflammation. Trends Cell Biol. 2014;24:313–20.PubMedCrossRef
62.
Li Y, Zheng JY, Liu JQ, Yang J, Liu Y, Wang C, et al. Succinate/NLRP3 inflammasome induces synovial fibroblast activation: therapeutical effects of clematichinenoside AR on arthritis. Front Immunol. 2016;7:532.PubMedPubMedCentral
63.
Li F, Xu W, Zhao S. Regulatory roles of metabolites in cell signaling networks. J Genet Genomics. 2013;40:367–74.PubMedCrossRef
64.
65.
de Molina Ramirez A, Banez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, et al. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004;64:6732–9.CrossRef
66.
de Molina Ramirez A, Gallego-Ortega D, Sarmentero-Estrada J, Lagares D, Gomez Del Pulgar T, Bandres E, et al. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol. 2008;40:1753–63.CrossRef
67.
de Molina Ramirez A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, de Molina Ramirez V, Cejas P, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007;8:889–97.CrossRef
68.
Guma M, Sanchez-Lopez E, Lodi A, Garcia-Carbonell R, Tiziani S, Karin M, et al. Choline kinase inhibition in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1399–407.PubMedCrossRef
69.
Lim HK, Choi YA, Park W, Lee T, Ryu SH, Kim SY, et al. Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway. J Biol Chem. 2003;278:45117–27.PubMedCrossRef
70.
Friday SC, Fox DA. Phospholipase D enzymes facilitate IL-17- and TNFalpha-induced expression of proinflammatory genes in rheumatoid arthritis synovial fibroblasts (RASF). Immunol Lett. 2016;174:9–18.PubMedCrossRef
71.
Gonzalez-Cabrera PJ, Brown S, Studer SM, Rosen H. S1P signaling: new therapies and opportunities. F1000Prime Rep. 2014;6:109.PubMedPubMedCentral
72.
Baker DA, Eudaly J, Smith CD, Obeid LM, Gilkeson GS. Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. Rheumatol Int. 2013;33:2677–81.PubMedCrossRef
73.
Hu PF, Chen Y, Cai PF, Jiang LF, Wu LD. Sphingosine-1-phosphate: a potential therapeutic target for rheumatoid arthritis. Mol Biol Rep. 2011;38:4225–30.PubMedCrossRef
74.
Zhao C, Fernandes MJ, Turgeon M, Tancrede S, Di Battista J, Poubelle PE, et al. Specific and overlapping sphingosine-1-phosphate receptor functions in human synoviocytes: impact of TNF-alpha. J Lipid Res. 2008;49:2323–37.PubMedCrossRef
75.
Bourgoin SG, Zhao C. Autotaxin and lysophospholipids in rheumatoid arthritis. Curr Opin Investig Drugs. 2010;11:515–26.PubMed
76.
Miyabe Y, Miyabe C, Iwai Y, Yokoyama W, Sekine C, Sugimoto K, et al. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade. Arthritis Res Ther. 2014;16:461.PubMedPubMedCentralCrossRef
77.
Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med. 2012;209:925–33.PubMedPubMedCentralCrossRef
78.
Fuchs B, Schiller J, Wagner U, Hantzschel H, Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem. 2005;38:925–33.PubMedCrossRef
79.
Chen M, Lam BK, Luster AD, Zarini S, Murphy RC, Bair AM, et al. Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis. J Immunol. 2010;185:5503–11.PubMedPubMedCentralCrossRef
80.
Wu MY, Lin TH, Chiu YC, Liou HC, Yang RS, Fu WM. Involvement of 15-lipoxygenase in the inflammatory arthritis. J Cell Biochem. 2012;113:2279–89.PubMedCrossRef
81.
Frommer KW, Schaffler A, Rehart S, Lehr A, Muller-Ladner U, Neumann E. Free fatty acids: potential proinflammatory mediators in rheumatic diseases. Ann Rheum Dis. 2015;74:303–10.PubMedCrossRef
82.
Yeom M, Hahm DH, Sur BJ, Han JJ, Lee HJ, Yang HI, et al. Phosphatidylserine inhibits inflammatory responses in interleukin-1beta-stimulated fibroblast-like synoviocytes and alleviates carrageenan-induced arthritis in rat. Nutr Res. 2013;33:242–50.PubMedCrossRef
83.
Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology. 2007;44:59–74.PubMed
84.
Chen YQ, Chou PL, Cheng CY, Chiang CC, Wei MT, Chuang CT, et al. Microrheology of human synovial fluid of arthritis patients studied by diffusing wave spectroscopy. J Biophotonics. 2012;5:777–84.PubMedCrossRef
85.
Kosinska MK, Liebisch G, Lochnit G, Wilhelm J, Klein H, Kaesser U, et al. A lipidomic study of phospholipid classes and species in human synovial fluid. Arthritis Rheum. 2013;65:2323–33.PubMedCrossRef
86.
Kosinska MK, Liebisch G, Lochnit G, Wilhelm J, Klein H, Kaesser U, et al. Sphingolipids in human synovial fluid--a lipidomic study. PLoS One. 2014;9:e91769.PubMedPubMedCentralCrossRef
87.
Schwarz IM, Hills BA. Synovial surfactant: lamellar bodies in type B synoviocytes and proteolipid in synovial fluid and the articular lining. Br J Rheumatol. 1996;35:821–7.PubMedCrossRef
88.
Kosinska MK, Ludwig TE, Liebisch G, Zhang R, Siebert HC, Wilhelm J, et al. Articular joint lubricants during osteoarthritis and rheumatoid arthritis display altered levels and molecular species. PLoS One. 2015;10:e0125192.PubMedPubMedCentralCrossRef
89.
Trunfio-Sfarghiu AM, Berthier Y, Meurisse MH, Rieu JP. Role of nanomechanical properties in the tribological performance of phospholipid biomimetic surfaces. Langmuir. 2008;24:8765–71.PubMedCrossRef
90.
Sokolowska M, Chen LY, Eberlein M, Martinez-Anton A, Liu Y, Alsaaty S, et al. Low molecular weight hyaluronan activates cytosolic phospholipase A2alpha and eicosanoid production in monocytes and macrophages. J Biol Chem. 2014;289:4470–88.PubMedCrossRef
91.
Yoshioka Y, Kozawa E, Urakawa H, Arai E, Futamura N, Zhuo L, et al. Suppression of hyaluronan synthesis alleviates inflammatory responses in murine arthritis and in human rheumatoid synovial fibroblasts. Arthritis Rheum. 2013;65:1160–70.PubMedCrossRef
92.
Yang XY, Zheng KD, Lin K, Zheng G, Zou H, Wang JM, et al. Energy metabolism disorder as a contributing factor of rheumatoid arthritis: a comparative proteomic and metabolomic study. PLoS One. 2015;10:e0132695.PubMedPubMedCentralCrossRef
93.
Treuhaft PS, MCCarty DJ. Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum. 1971;14:475–84.PubMedCrossRef
94.
95.
Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;196:647–55.PubMedCrossRef
96.
Yang X, Lehotay M, Anastassiades T, Harrison M, Brockhausen I. The effect of TNF-alpha on glycosylation pathways in bovine synoviocytes. Biochem Cell Biol. 2004;82:559–68.PubMedCrossRef
97.
Del Rey MJ, Izquierdo E, Usategui A, Gonzalo E, Blanco FJ, Acquadro F, et al. The transcriptional response of normal and rheumatoid arthritis synovial fibroblasts to hypoxia. Arthritis Rheum. 2010;62:3584–94.PubMedCrossRef
98.
Tas SW, Maracle CX, Balogh E, Szekanecz Z. Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol. 2016;12:111–22.PubMedCrossRef
99.
Veale DJ, Fearon U. Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting. Best Practice Res. 2006;20:941–7.CrossRef
100.
Lu Y, Yu SS, Zong M, Fan SS, Lu TB, Gong RH, et al. Glucose-6-phosphate isomerase (G6PI) mediates hypoxia-induced angiogenesis in rheumatoid arthritis. Sci Rep. 2017;7:40274.PubMedPubMedCentralCrossRef
101.
Peters MA, Wendholt D, Strietholt S, Frank S, Pundt N, Korb-Pap A, et al. The loss of alpha2beta1 integrin suppresses joint inflammation and cartilage destruction in mouse models of rheumatoid arthritis. Arthritis Rheum. 2012;64:1359–68.PubMedCrossRef
102.
McInnes IB, Leung BP, Liew FY. Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res. 2000;2:374–8.PubMedPubMedCentralCrossRef
103.
Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Alpha 4/beta 1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J Immunol. 1992;149:1424–31.PubMed
104.
Ata R, Antonescu CN. Integrins and cell metabolism: an intimate relationship impacting cancer. Int J Mol Sci. 2017;18(1):189.
105.
106.
Yang L, Hou Y, Yuan J, Tang S, Zhang H, Zhu Q, et al. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways. Oncotarget. 2015;6:25755–69.PubMedPubMedCentralCrossRef
107.
Lauzier A, Lavoie RR, Charbonneau M, Gouin-Boisvert B, Harper K, Dubois CM. Snail is a critical mediator of invadosome formation and joint degradation in arthritis. Am J Pathol. 2016;186:359–74.PubMedCrossRef
108.
Xue SN, Lei J, Lin DZ, Yang C, Yan L. Changes in biological behaviors of rat dermal fibroblasts induced by high expression of MMP9. World J Emerg Med. 2014;5:139–43.PubMedPubMedCentralCrossRef
109.
Zhao W, Zhang C, Shi M, Zhang J, Li M, Xue X, et al. The discoidin domain receptor 2/annexin A2/matrix metalloproteinase 13 loop promotes joint destruction in arthritis through promoting migration and invasion of fibroblast-like synoviocytes. Arthritis Rheumatol. 2014;66:2355–67.PubMedCrossRef
110.
Sabeh F, Fox D, Weiss SJ. Membrane-type I matrix metalloproteinase-dependent regulation of rheumatoid arthritis synoviocyte function. J Immunol. 2010;184:6396–406.PubMedCrossRef
111.
Laragione T, Brenner M, Li W, Gulko PS. Cia5d regulates a new fibroblast-like synoviocyte invasion-associated gene expression signature. Arthritis Res Ther. 2008;10:R92.PubMedPubMedCentralCrossRef
112.
Matsumoto S, Muller-Ladner U, Gay RE, Nishioka K, Gay S. Ultrastructural demonstration of apoptosis, Fas and Bcl-2 expression of rheumatoid synovial fibroblasts. J Rheumatol. 1996;23:1345–52.PubMed
113.
Lee SY, Kwok SK, Son HJ, Ryu JG, Kim EK, Oh HJ, et al. IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation. Arthritis Res Ther. 2013;15:R31.PubMedPubMedCentralCrossRef
114.
Zhang HG, Wang Y, Xie JF, Liang X, Liu D, Yang P, et al. Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum. 2001;44:1555–67.PubMedCrossRef
115.
You X, Boyle DL, Hammaker D, Firestein GS. PUMA-mediated apoptosis in fibroblast-like synoviocytes does not require p53. Arthritis Res Ther. 2006;8:R157.PubMedPubMedCentralCrossRef
116.
Cha HS, Rosengren S, Boyle DL, Firestein GS. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis Rheum. 2006;54:587–92.PubMedCrossRef
117.
118.
Yu X, Li S. Non-metabolic functions of glycolytic enzymes in tumorigenesis. Oncogene. 2016;36:2629-36.
119.
Hu F, Yang S, Zhao D, Zhu S, Wang Y, Li J. Moderate extracellular acidification inhibits capsaicin-induced cell death through regulating calcium mobilization, NF-kappaB translocation and ROS production in synoviocytes. Biochem Biophys Res Commun. 2012;424:196–200.PubMedCrossRef
120.
Xu K, Xu P, Yao JF, Zhang YG, Hou WK, Lu SM. Reduced apoptosis correlates with enhanced autophagy in synovial tissues of rheumatoid arthritis. Inflamm Res. 2013;62:229–37.PubMedCrossRef
121.
Shin YJ, Han SH, Kim DS, Lee GH, Yoo WH, Kang YM, et al. Autophagy induction and CHOP under-expression promotes survival of fibroblasts from rheumatoid arthritis patients under endoplasmic reticulum stress. Arthritis Res Ther. 2010;12:R19.PubMedPubMedCentralCrossRef
122.
Ruan GX, Kazlauskas A. Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/Akt and promote angiogenesis. J Biol Chem. 2013;288:21161–72.PubMedPubMedCentralCrossRef
123.
Xiao F, Yu J, Guo Y, Deng J, Li K, Du Y, et al. Effects of individual branched-chain amino acids deprivation on insulin sensitivity and glucose metabolism in mice. Metabolism. 2014;63:841–50.PubMedCrossRef
124.
Becker JC, Andersen MH, Schrama D, Thor SP. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother. 2013;62:1137–48.PubMedCrossRef
125.
126.
127.
Bottini N, Firestein GS. Epigenetics in rheumatoid arthritis: a primer for rheumatologists. Curr Rheumatol Rep. 2013;15:372.PubMedCrossRef
128.
129.
130.
Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun Rev. 2011;10:519–24.PubMedCrossRef
131.
Jungel A, Ospelt C, Gay S. What can we learn from epigenetics in the year 2009? Curr Opin Rheumatol. 2010;22:284–92.PubMedCrossRef
132.
Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9:24–33.PubMedCrossRef
133.
134.
Anderson OS, Sant KE, Dolinoy DC. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J Nutr Biochem. 2012;23:853–9.PubMedPubMedCentralCrossRef
135.
Chango A, Pogribny IP. Considering maternal dietary modulators for epigenetic regulation and programming of the fetal epigenome. Nutrients. 2015;7:2748–70.PubMedPubMedCentralCrossRef
136.
137.
138.
Tomasetti M, Amati M, Santarelli L, Neuzil J. MicroRNAs in metabolic re-programming and their role in tumorigenesis. Int J Mol Sci. 2016;18:17(5). doi:10.​3390/​ijms17050754.
139.
140.
Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12:829–46.PubMedCrossRef
141.
Lories RJ, Derese I, De Bari C, Luyten FP. In vitro growth rate of fibroblast-like synovial cells is reduced by methotrexate treatment. Ann Rheum Dis. 2003;62:568–71.PubMedPubMedCentralCrossRef
142.
Vergne-Salle P, Leger DY, Bertin P, Treves R, Beneytout JL, Liagre B. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine. 2005;31:335–48.PubMedCrossRef
Metadata
Title
Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis
Authors
Marta F. Bustamante
Ricard Garcia-Carbonell
Katrijn D. Whisenant
Monica Guma
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2017
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-017-1303-3

Other articles of this Issue 1/2017

Arthritis Research & Therapy 1/2017 Go to the issue

Research article

Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis

Research article

Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts

Research article

Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study

Research article

Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis

Research article

Increased serum levels of fractalkine and mobilisation of CD34+CD45− endothelial progenitor cells in systemic sclerosis

Research article

Varying the item format improved the range of measurement in patient-reported outcome measures assessing physical function
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits